CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ

被引:332
作者
Mumberg, D
Monach, PA
Wanderling, S
Philip, M
Toledano, AY
Schreiber, RD
Schreiber, H
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA
[3] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA
关键词
D O I
10.1073/pnas.96.15.8633
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CD4(+) T cells can eliminate tumor cells in vivo in the absence of CD8(+) T cells. We have CD4(+) T cells specific for a MHC class II-restricted, tumor-specific peptide derived from a mutant ribosomal protein expressed by the UV light-induced tumor 6132A-PRO. By using neutralizing mAb specific for murine IFN-gamma and adoptive transfer of CD4(+) T cells into severe combined immunodeficient mice, we show that anti-IFN-gamma treatment abolishes the CD4(+) T cell-mediated rejection of the tumor cells in vivo. The tumor cells were MHC class II negative, and IFN-gamma did not induce MHC class II expression in vitro. Therefore, the tumor-specific antigenic peptide must be presented by host cells and not the tumor cells. Tumor cells transduced to secrete IFN-gamma had a markedly reduced growth rate in severe combined immunodeficient mice, but IFN-gamma did not inhibit the growth of the tumor cells in vitro. Furthermore, tumor cells stably expressing a dominant-negative truncated form of the murine IFN-gamma receptor a chain, and therefore insensitive to IFN-gamma, nevertheless were rejected by the adoptively transferred CD4(+) T cells. Thus, host cells, and not tumor cells, seem to be the target of IFN-gamma. Together, these results show that CD4(+) T cells can eliminate IFN-gamma-insensitive, MHC class II-negative cancer cells by an indirect mechanism that depends on IFN-gamma.
引用
收藏
页码:8633 / 8638
页数:6
相关论文
共 42 条
[1]  
Agresti A., 1990, Analysis of categorical data
[2]  
Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9
[3]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[4]   BIOLOGICAL IMPLICATIONS OF HLA-DR EXPRESSION IN TUMORS [J].
CABRERA, T ;
RUIZCABELLO, F ;
GARRIDO, F .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1995, 41 (04) :398-406
[5]   2 TYPES OF MOUSE HELPER T-CELL CLONE .3. FURTHER DIFFERENCES IN LYMPHOKINE SYNTHESIS BETWEEN TH1 AND TH2 CLONES REVEALED BY RNA HYBRIDIZATION, FUNCTIONALLY MONOSPECIFIC BIOASSAYS, AND MONOCLONAL-ANTIBODIES [J].
CHERWINSKI, HM ;
SCHUMACHER, JH ;
BROWN, KD ;
MOSMANN, TR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (05) :1229-1244
[6]   Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis [J].
Coughlin, CM ;
Salhany, KE ;
Gee, MS ;
LaTemple, DC ;
Kotenko, S ;
Ma, XJ ;
Gri, G ;
Wysocka, M ;
Kim, JE ;
Liu, L ;
Liao, F ;
Farber, JM ;
Pestka, S ;
Trinchieri, G ;
Lee, WMF .
IMMUNITY, 1998, 9 (01) :25-34
[7]  
DIGHE AS, 1993, J BIOL CHEM, V268, P10645
[8]   ENHANCED IN-VIVO GROWTH AND RESISTANCE TO REJECTION OF TUMOR-CELLS EXPRESSING DOMINANT-NEGATIVE IFN-GAMMA RECEPTORS [J].
DIGHE, AS ;
RICHARDS, E ;
OLD, LJ ;
SCHREIBER, RD .
IMMUNITY, 1994, 1 (06) :447-456
[9]   VACCINATION WITH IRRADIATED TUMOR-CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTITUMOR IMMUNITY [J].
DRANOFF, G ;
JAFFEE, E ;
LAZENBY, A ;
GOLUMBEK, P ;
LEVITSKY, H ;
BROSE, K ;
JACKSON, V ;
HAMADA, H ;
PARDOLL, D ;
MULLIGAN, RC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3539-3543